J. C. Jennette and R. J. Falk, Small-vessel vasculitis, N Engl J Med, vol.337, pp.1512-1535, 1997.

J. C. Jennette, R. J. Falk, P. A. Bacon, N. Basu, M. C. Cid et al., 2012 revised international chapel hill consensus conference nomenclature of vasculitides, Arthritis Rheum, vol.65, pp.1-11, 2013.

L. Guillevin, B. Durand-gasselin, R. Cevallos, M. Gayraud, F. Lhote et al., Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients, Arthritis Rheum, vol.42, pp.421-451, 1999.

J. D. Finkielman, A. S. Lee, A. M. Hummel, M. A. Viss, G. L. Jacob et al., ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis, Am J Med, vol.120, pp.9-14, 2007.

J. C. Jennette and P. H. Nachman, ANCA glomerulonephritis and vasculitis, Clin J Am Soc Nephrol, vol.12, pp.1680-91, 2017.

M. V. Talor, J. H. Stone, J. Stebbing, J. Barin, N. R. Rose et al., Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA): minor target antigens in ANCA-associated vasculitis, Clin Exp Immunol, vol.150, pp.42-50, 2007.

R. Kettritz, With complements from ANCA mice, J Am Soc Nephrol, vol.25, pp.207-216, 2014.

J. C. Jennette, A. S. Wilkman, and R. J. Falk, Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis, Am J Pathol, vol.135, issue.5, pp.921-951, 1989.

G. Xing, M. Chen, G. Liu, P. Heeringa, J. Zhang et al., Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis, J Clin Immunol, vol.29, pp.282-91, 2009.

A. Gigante, C. Salviani, K. Giannakakis, E. Rosato, B. Barbano et al., Clinical and histological outcome predictors in renal limited pauci-immune crescentic glomerulonephritis: a single centre experience, Int J Immunopathol Pharmacol, vol.25, pp.287-92, 2012.

R. J. Falk, R. S. Terrell, L. A. Charles, and J. C. Jennette, Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro, Proc Natl Acad Sci, vol.87, pp.4115-4124, 1990.

D. Huugen, H. Xiao, A. Van-esch, R. J. Falk, C. J. Peutz-kootstra et al., Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha, Am J Pathol, vol.167, pp.47-58, 2005.

D. Reumaux, P. J. Vossebeld, D. Roos, and A. J. Verhoeven, Effect of tumor necrosis factorinduced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies, Blood, vol.86, pp.3189-95, 1995.

V. Witko-sarsat, P. Lesavre, S. Lopez, G. Bessou, C. Hieblot et al., A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis, J Am Soc Nephrol, vol.10, pp.1224-1257, 1999.

S. Brachemi, A. Mambole, F. Fakhouri, L. Mouthon, L. Guillevin et al., Increased membrane expression of proteinase 3 during neutrophil adhesion in the presence of anti proteinase 3 antibodies, J Am Soc Nephrol, vol.18, pp.2330-2339, 2007.

A. J. Porges, P. B. Redecha, W. T. Kimberly, E. Csernok, W. L. Gross et al., Antineutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa, J Immunol, vol.153, pp.1271-80, 1994.

A. Schreiber, F. C. Luft, and R. Kettritz, Phagocyte NADPH oxidase restrains the inflammasome in ANCA-induced GN, J Am Soc Nephrol, vol.26, pp.411-435, 2015.

J. Berthelot, L. Goff, B. Neel, A. Maugars, Y. Hamidou et al., NETosis: at the crossroads of rheumatoid arthritis, lupus, and vasculitis, Joint Bone Spine, vol.84, pp.255-62, 2017.

K. Kessenbrock, M. Krumbholz, U. Schönermarck, W. Back, W. L. Gross et al., Netting neutrophils in autoimmune small-vessel vasculitis, Nat Med, vol.15, pp.623-628, 2009.

S. Sangaletti, C. Tripodo, C. Chiodoni, C. Guarnotta, B. Cappetti et al., Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity, Blood, vol.120, pp.3007-3025, 2012.

D. Söderberg and M. Segelmark, Neutrophil extracellular traps in ANCA-associated vasculitis, Front Immunol, vol.7, 2016.

C. Lange, E. Csernok, F. Moosig, and J. U. Holle, Immune stimulatory effects of neutrophil extracellular traps in granulomatosis with polyangiitis, Clin Exp Rheumatol, vol.35, pp.33-42, 2017.

B. Brilland, Autoimmunity Reviews, vol.19, p.102424, 2020.

V. Witko-sarsat, N. Reuter, and L. Mouthon, Interaction of proteinase 3 with its associated partners: implications in the pathogenesis of Wegener's granulomatosis, Curr Opin Rheumatol, vol.22, pp.1-7, 2010.

A. Schreiber, H. Xiao, J. C. Jennette, W. Schneider, F. C. Luft et al., C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis, J Am Soc Nephrol, vol.20, pp.289-98, 2009.

K. E. Foreman, A. A. Vaporciyan, B. K. Bonish, M. L. Jones, K. J. Johnson et al., C5a-induced expression of P-selectin in endothelial cells, J Clin Invest, vol.94, pp.1147-55, 1994.

I. U. Schraufstatter, K. Trieu, L. Sikora, P. Sriramarao, and R. Discipio, Complement c3a and c5a induce different signal transduction cascades in endothelial cells, J Immunol, vol.169, pp.2102-2112, 2002.

P. Lenert and A. Lenert, Current and emerging treatment options fo ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents, Drug Des Devel Ther, p.333, 2015.

M. Mcclure, S. Gopaluni, J. D. Jones, and R. , B cell therapy in ANCA-associated vasculitis: current and emerging treatment options, Nat Rev Rheumatol, vol.14, pp.580-91, 2018.

W. H. Abdulahad, P. Lamprecht, and C. Kallenberg, T-helper cells as new players in ANCA-associated vasculitides, Arthritis Res Ther, vol.13, p.236, 2011.

B. P. Morgan and C. L. Harris, Complement, a target for therapy in inflammatory and degenerative diseases, Nat Rev Drug Discov, vol.14, pp.857-77, 2015.

L. A. Trouw, M. C. Pickering, and A. M. Blom, The complement system as a potential therapeutic target in rheumatic disease, Nat Rev Rheumatol, vol.13, pp.538-585, 2017.

J. M. Thurman and V. M. Holers, The central role of the alternative complement pathway in human disease, J Immunol, vol.176, pp.1305-1315, 2006.

M. Chen, M. R. Daha, and C. Kallenberg, The complement system in systemic autoimmune disease, J Autoimmun, vol.34, pp.276-86, 2010.

D. Huugen, A. Van-esch, H. Xiao, C. Peutz-kootstra, W. Buurman et al., Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice, Kidney Int, vol.71, pp.646-54, 2007.

D. R. Mathern and P. S. Heeger, Molecules great and small: the complement system, Clin J Am Soc Nephrol, vol.10, pp.1636-50, 2015.

H. Xiao, P. Heeringa, P. Hu, Z. Liu, M. Zhao et al., Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice, J Clin Invest, vol.110, pp.955-63, 2002.

H. Pfister, M. Ollert, L. F. Fröhlich, L. Quintanilla-martinez, T. V. Colby et al., Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo, Blood, vol.104, pp.1411-1419, 2004.

Y. M. Van-der-geld, T. Hellmark, D. Selga, P. Heeringa, M. G. Huitema et al., Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes, Ann Rheum Dis, vol.66, pp.1679-82, 2007.

A. D. Salama and M. A. Little, Animal models of antineutrophil cytoplasm antibody-associated vasculitis, Curr Opin Rheumatol, vol.24, pp.1-7, 2012.

M. A. Little, Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo, Blood, vol.106, pp.2050-2058, 2005.

H. Xiao, A. Schreiber, P. Heeringa, R. J. Falk, and J. C. Jennette, Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies, Am J Pathol, vol.170, pp.52-64, 2007.

M. Shingu, S. Nonaka, H. Nishimukai, M. Nobunaga, H. Kitamura et al., Activation of complement in normal serum by hydrogen peroxide and hydrogen peroxide-related oxygen radicals produced by activated neutrophils, Clin Exp Immunol, vol.90, pp.72-80, 1992.

W. Vogt, Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes, Immunobiology, vol.195, pp.80050-80057, 1996.

U. Wirthmueller, B. Dewald, M. Thelen, M. K. Schäfer, C. Stover et al., Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils, J Immunol, vol.158, pp.4444-51, 1997.

S. J. Freeley, R. J. Popat, K. Parmar, M. Kolev, B. J. Hunt et al., Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5: complement and vasculitis, J Pathol, vol.240, pp.61-71, 2016.

H. Xiao, D. J. Dairaghi, J. P. Powers, L. S. Ertl, T. Baumgart et al., C5a Receptor (CD88) blockade protects against MPO-ANCA GN, J Am Soc Nephrol, vol.25, pp.225-256, 2014.

S. R. Marder, D. E. Chenoweth, I. M. Goldstein, and H. D. Perez, Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg, J Immunol, vol.134, pp.3325-3356, 1985.

M. C. Perianayagam, V. S. Balakrishnan, A. J. King, B. Pereira, and B. L. Jaber, C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway, Kidney Int, vol.61, pp.456-63, 2002.

I. J. Laudes, J. C. Chu, S. Sikranth, M. Huber-lang, R. Guo et al., Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis, Am J Pathol, vol.160, issue.10, pp.61133-61142, 2002.

T. E. Mollnes, O. Brekke, M. Fung, H. Fure, D. Christiansen et al., Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation, Blood, vol.100, pp.1869-77, 2002.

E. L. Becker, J. C. Kermode, P. H. Naccache, R. Yassin, M. L. Marsh et al., The inhibition of neutrophil granule enzyme secretion and chemotaxis by pertussis toxin, J Cell Biol, vol.100, pp.1641-1647, 1985.

N. P. Gerard and C. Gerard, The chemotactic receptor for human C5a anaphylatoxin, Nature, vol.349, pp.614-621, 1991.

M. Ohno, T. Hirata, M. Enomoto, T. Araki, H. Ishimaru et al., A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells, Mol Immunol, vol.37, pp.407-419, 2000.

J. Dunkelberger, L. Zhou, T. Miwa, and W. Song, C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity, J Immunol, vol.188, pp.4032-4074, 2012.

C. M. Karsten, Y. Laumonnier, B. Eurich, F. Ender, K. Bröker et al., Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse, J Immunol, vol.194, pp.1841-55, 2015.

. Collectif, Encyclopedia of immunobiology, 2016.

S. Okinaga, D. Slattery, A. Humbles, Z. Zsengeller, O. Morteau et al., C5L2, a nonsignaling C5A binding protein, Biochemistry, vol.42, pp.9406-9421, 2003.

N. P. Gerard, B. Lu, P. Liu, S. Craig, Y. Fujiwara et al., An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2, J Biol Chem, vol.280, pp.39677-80, 2005.

A. Scola, K. Johswich, B. P. Morgan, A. Klos, and P. N. Monk, The human complement fragment receptor, C5L2, is a recycling decoy receptor, Mol Immunol, vol.46, pp.1149-62, 2009.

C. E. Bamberg, C. R. Mackay, H. Lee, D. Zahra, J. Jackson et al., The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction, J Biol Chem, vol.285, pp.7633-7677, 2010.

N. Chen, C. Mirtsos, D. Suh, Y. Lu, W. Lin et al., C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a, Nature, vol.446, pp.203-210, 2007.

D. Rittirsch, M. A. Flierl, B. A. Nadeau, D. E. Day, M. Huber-lang et al., Functional roles for C5a receptors in sepsis, Nat Med, vol.14, pp.551-558, 2008.

A. Schreiber, H. Xiao, R. J. Falk, and J. C. Jennette, Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies, J Am Soc Nephrol, vol.17, pp.3355-64, 2006.

L. Camous, L. Roumenina, S. Bigot, S. Brachemi, V. Frémeaux-bacchi et al., Complement alternative pathway acts as a positive feedback amplification of neutrophil activation, Blood, vol.117, pp.1340-1349, 2011.

J. Hao, L. Meng, P. Xu, M. Chen, and M. Zhao, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation, PLoS One, vol.7, 2012.

S. Gou, J. Yuan, M. Chen, F. Yu, and M. Zhao, Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis, Kidney Int, vol.83, pp.129-166, 2013.

J. Yuan, S. Gou, J. Huang, J. Hao, M. Chen et al., C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Arthritis Res Ther, vol.14, 2012.

Y. Molad, A. Tovar, and S. Ofer-shiber, Association of low serum complement C3 with reduced patient and renal survival in antimyeloperoxidase-associated small-vessel vasculitis, Nephron Clin Pract, vol.126, pp.67-74, 2014.

L. Manenti, A. Vaglio, E. Gnappi, U. Maggiore, L. Allegri et al., Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis, Clin J Am Soc Nephrol, vol.10, pp.2143-51, 2015.

A. Langs, V. Demiselle, J. Lavigne, C. Brilland, B. Duveau et al., Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis, PLoS One, vol.11, 2016.

S. Fukui, N. Iwamoto, M. Umeda, A. Nishino, Y. Nakashima et al., Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis, Medicine (Baltimore), vol.95, 2016.

S. Deshayes, A. Aouba, K. Khoy, D. Mariotte, T. Lobbedez et al., Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis, PLoS One, vol.13, 2018.

H. Watanabe, E. Noguchi, K. Shio, H. Iwadate, H. Kobayashi et al., Usefulness of complement split product, Bb, as a clinical marker for disease activity of lupus nephritis, Fukushima J Med Sci, vol.52, pp.103-112, 2006.

M. T. Ganter, K. Brohi, M. J. Cohen, L. A. Shaffer, M. C. Walsh et al., Autoimmunity Reviews, vol.19, p.102424, 2020.

, alternative pathway in the early complement activation following major trauma, Shock, vol.28, pp.29-34, 2007.

I. Y. Pavlov, D. Forest, N. Delgado, and J. C. , Specificity of EIA immunoassay for complement factor Bb testing, Clin Lab, vol.57, pp.225-233, 2011.

S. Gou, J. Yuan, C. Wang, M. Zhao, and M. Chen, Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN

, Clin J Am Soc Nephrol, vol.8, pp.1884-91, 2013.

M. K. Pangburn, R. D. Schreiber, and H. J. Müller-eberhard, Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution, J Exp Med, vol.146, pp.257-70, 1977.

H. Jarva, T. S. Jokiranta, J. Hellwage, P. F. Zipfel, and S. Meri, Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11, J Immunol, vol.163, pp.3957-62, 1999.

M. Noris and G. Remuzzi, Atypical hemolytic-uremic syndrome, N Engl J Med, vol.361, pp.1676-87, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01793663

A. Servais, L. Noël, L. T. Roumenina, L. Quintrec, M. Ngo et al., Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney Int, vol.82, pp.454-64, 2012.

S. Chen, F. Wang, Z. Li, Y. F. Zhao, M. Chen et al., Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis, Arthritis Res Ther, vol.17, 2015.

S. Chen, F. Wang, Z. Li, Y. F. Chen, M. Zhao et al., Myeloperoxidase influences the complement regulatory activity of complement factor H, Rheumatology (Oxford, 2018.

S. Sethi, M. Haas, G. S. Markowitz, D. 'agati, V. D. Rennke et al., Mayo clinic/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN, J Am Soc Nephrol, vol.27, pp.1278-87, 2016.

J. C. Jennette and R. J. Falk, Pathogenesis of antineutrophil cytoplasmic autoantibodymediated disease, Nat Rev Rheumatol, vol.10, pp.463-73, 2014.

C. Hu, Cutaneous manifestations of Wegener granulomatosis, Arch Dermatol, vol.113, p.175, 1977.

M. M. Van-timmeren, M. Chen, and P. Heeringa, Review article: pathogenic role of complement activation in anti-neutrophil cytoplasmic auto-antibody-associated vasculitis, Nephrology, vol.14, pp.16-25, 2009.

M. Haas and J. A. Eustace, Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases, Kidney Int, vol.65, pp.2145-52, 2004.

M. Hilhorst, P. Van-paassen, H. Van-rie, N. Bijnens, P. Heerings-rewinkel et al., Complement in ANCA-associated glomerulonephritis, Nephrol Dial Transplant, vol.32, pp.1302-1315, 2017.

M. Schulze, C. J. Pruchno, M. Burns, P. J. Baker, R. J. Johnson et al., Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis, Am J Pathol, vol.142, pp.179-87, 1993.

M. Chen, G. Xing, F. Yu, G. Liu, and M. Zhao, Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis, Nephrol Dial Transplant, vol.24, pp.1247-52, 2008.

G. Xing, M. Chen, G. Liu, X. Zheng, E. Zhao et al., Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis, J Clin Immunol, vol.30, pp.144-56, 2010.

S. Sethi, S. H. Nasr, D. Vriese, A. S. Fervenza, and F. C. , C4d as a diagnostic tool in proliferative GN, J Am Soc Nephrol, vol.26, pp.2852-2861, 2015.

S. Sethi, L. Zand, D. Vriese, A. S. Specks, U. Vrana et al., Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis, Nephrol Dial Transplant, vol.32, pp.139-184, 2017.

F. C. Fervenza, R. Smith, and S. Sethi, Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis, Am J Kidney Dis, vol.60, pp.126-158, 2012.

R. Huey and T. E. Hugli, Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN), J Immunol, vol.135, pp.2063-2071, 1985.

S. A. Cain and P. N. Monk, The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg 74, J Biol Chem, vol.277, pp.7165-7174, 2002.

L. Cheng, S. Gou, H. Qiu, L. Ma, and P. Fu, Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: complement regulatory proteins in AAV, Clin Exp Immunol, vol.191, pp.116-140, 2018.

B. Wilde, P. Van-paassen, O. Witzke, and J. Tervaert, New pathophysiological insights and treatment of ANCA-associated vasculitis, Kidney Int, vol.79, pp.599-612, 2011.

P. Bekker, D. Dairaghi, L. Seitz, M. Leleti, Y. Wang et al., Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study, PLoS One, vol.11, 2016.

D. Jayne, A. N. Bruchfeld, L. Harper, M. Schaier, M. C. Venning et al., Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis, J Am Soc Nephrol, vol.28, pp.2756-67, 2017.

P. A. Merkel, J. Niles, R. Jimenez, R. F. Spiera, B. H. Rovin et al., A Randomized clinical trial of CCX168, an orally administered C5aR inhibitor for treatment of patients with ANCA-associated vasculitis (abstract), Arthritis Rheumatol, vol.68, p.2016, 2016.

A. J. Vickers, The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study, BMC Med Res Methodol, vol.1, 2001.

F. E. Harrell and J. C. Slaughter, Biostatistics for biomedical research, 2016.

J. M. Bland and D. G. Altman, Comparisons against baseline within randomised groups are often used and can be highly misleading, Trials, vol.12, 2011.

A. Chemocentryx, Phase 3 clinical trial of CCX168 (avacopan) in patients with ANCA-associated vasculitis (ADVOCATE) (NCT02994927), 2016.

L. Guillevin, Maintenance treatment of ANCA-associated vasculitides, Clin Exp Rheumatol, vol.35, pp.199-201, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01064298

C. King and L. Harper, Avoidance of harm from treatment for ANCA-associated vasculitis, Curr Treatm Opt Rheumatol, vol.3, pp.230-273, 2017.

M. A. Little, P. Nightingale, C. A. Verburgh, T. Hauser, D. Groot et al., Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis, Ann Rheum Dis, vol.69, pp.1036-1079, 2010.

J. G. Mcgregor, S. L. Hogan, Y. Hu, C. E. Jennette, R. J. Falk et al., Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease, Clin J Am Soc Nephrol, vol.7, pp.240-247, 2012.

R. J. Pepper, S. P. Mcadoo, S. M. Moran, D. Kelly, J. Scott et al., A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis, Rheumatology, 2018.

S. P. Mcadoo, N. Medjeral-thomas, S. Gopaluni, A. Tanna, N. Mansfield et al., Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis, Nephrol Dial Transplant, 2018.

B. Brilland, Autoimmunity Reviews, vol.19, p.102424, 2020.